The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 10, 2017

Filed:

Aug. 24, 2015
Applicant:

The Texas A&m University System, College Station, TX (US);

Inventors:

James Sacchettini, College Station, TX (US);

Niam Zhou, College Station, TX (US);

Dwight Baker, College Station, TX (US);

Steven A. Maxwell, College Station, TX (US);

Deeann Wallis, College Station, TX (US);

Assignee:

The Texas A&M University System, College Station, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/00 (2006.01); A61K 31/435 (2006.01); A61K 31/7034 (2006.01); A61K 31/395 (2006.01); A61K 45/06 (2006.01); A61K 31/122 (2006.01); A61K 31/136 (2006.01); A61K 31/337 (2006.01); A61K 31/4745 (2006.01); A61K 31/475 (2006.01); A61K 31/5377 (2006.01); A61K 31/573 (2006.01); A61K 31/675 (2006.01); A61K 31/69 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); A61K 33/24 (2006.01); A61K 38/08 (2006.01); C07D 498/22 (2006.01); G01N 33/58 (2006.01); G01N 33/84 (2006.01);
U.S. Cl.
CPC ...
A61K 31/395 (2013.01); A61K 31/122 (2013.01); A61K 31/136 (2013.01); A61K 31/337 (2013.01); A61K 31/435 (2013.01); A61K 31/475 (2013.01); A61K 31/4745 (2013.01); A61K 31/5377 (2013.01); A61K 31/573 (2013.01); A61K 31/675 (2013.01); A61K 31/69 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 33/24 (2013.01); A61K 38/08 (2013.01); A61K 45/06 (2013.01); C07D 498/22 (2013.01); G01N 33/582 (2013.01); G01N 33/84 (2013.01); G01N 2800/52 (2013.01);
Abstract

The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient.


Find Patent Forward Citations

Loading…